TABLE 4.
Relationship between clinicopathological factors of patients with functional neuroendocrine tumors and postoperative symptom improvement
| Variable | Symptom improvement |
P value | |
|---|---|---|---|
| No, n (%) | Yes, n (%) | ||
| Known genetic syndrome | 9 (52.9%) | 16 (14.8%) | 0.001 |
| Type of functional tumor | 0.014 | ||
| Insulinoma | 5 (29.4%) | 63 (58.3%) | |
| Gastrinoma | 11 (64.7%) | 30 (27.8%) | |
| Other | 1 (5.9%) | 15 (13.9%) | |
| Multifocal | 6 (35.3%) | 22 (20.4%) | 0.290 |
| Tumor location | 0.091 | ||
| Pancreas | 12 (70.6%) | 88 (81.5%) | |
| Duodenum | 4 (23.5%) | 12 (11.1%) | |
| Liver | 0 (0%) | 4 (3.7%) | |
| Ampulla | 0 (0%) | 4 (3.7%) | |
| Tumor differentiation | 0.601 | ||
| Well | 13 (100%) | 88 (98.9%) | |
| Moderate | 0 (0%) | 1 (1.1%) | |
| Ki67 | 0.652 | ||
| < 3% | 6 (54.5%) | 41 (65.1%) | |
| 3%-20% | 5 (45.5%) | 21 (33.3%) | |
| > 20% | 0 (0%) | 1 (1.6%) | |
| LVI | 4 (50.0%) | 24 (27.0%) | 0.332 |
| PNI | 1 (20.0%) | 8 (9.9%) | 1.0 |
| Lymph node positive | 7 (50.0%) | 20 (27.8%) | 0.185 |
| Resection status | 0.007 | ||
| R0 | 9 (52.9%) | 91 (84.3%) | |
| R1 | 8 (47.1%) | 17 (15.7%) | |
Abbreviations: LVI, lymphovascular invasion; PNI, perineural invasion